Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - 65
Updated:3/28/2019
Start Date:April 23, 2018
End Date:May 15, 2020
Contact:Debbie Griffin, RN
Email:dgriffin3@kumc.edu
Phone:913-588-7691

Use our guide to learn which trials are right for you!

The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like
protein) in the urine that is changed after treatment of hydralazine.


Inclusion Criteria:

- Confirmed diagnosis of ADPKD

- estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2

Exclusion Criteria:

- History of systemic lupus erythematous or other rheumatologic disorder

- Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males

- Blood pressure < 120/80 without anti-hypertensive

- Angina pectoris or myocardial infarction in the last 6 months

- Liver disease

- Allergy to hydralazine
We found this trial at
1
site
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials